electroCore, Inc. will announce Q3 financial results on November 5, 2025, followed by a management webinar.
Quiver AI Summary
electroCore, Inc. will announce its financial results for the third quarter of 2025 on November 5, 2025, after market close, followed by a webinar at 4:30 PM EST to discuss the results and answer investor questions. The company's mission is to enhance health and quality of life through its bioelectronic technologies, including its prescription products gammaCore and Quell for chronic pain management, as well as its wellness products Truvaga and TAC-STIM. Interested investors can join the webinar using the provided dial-in information and registration link. For more details, visit their website or contact investor relations.
Potential Positives
- Announcement of the financial results for Q3 2025 indicates the company is actively engaging with investors and maintaining transparency about its performance.
- The hosting of a webinar for financial results demonstrates a commitment to stakeholder communication and allows for direct interaction with investors.
- The company's focus on innovative non-invasive bioelectronic technologies highlights its position in a growing market addressing health and wellness needs.
- Introduction of leading prescription products and consumer wellness technologies showcases the company's diverse product portfolio and potential for revenue growth.
Potential Negatives
- The release does not provide any specific financial results or performance metrics, which may lead to investor uncertainty and speculation about the company's financial health.
- There is no mention of growth strategies or future outlook, which could raise concerns among investors about the company's direction and market positioning.
FAQ
When will electroCore report its third quarter financial results?
electroCore will report its third quarter financial results on November 5, 2025, after market close.
What time is the webinar for the financial results?
The webinar will take place at 4:30 PM EST on November 5, 2025.
How can I access the webinar for electroCore's financial results?
Investors can access the webinar by dialing (646) 931-3860 and using Webinar ID: 822 9598 1338, Passcode: 454695.
What products does electroCore focus on?
electroCore focuses on non-invasive bioelectronic technologies for treating chronic pain and promoting wellness with products like gammaCore and Quell.
Where can I find more information about electroCore?
Additional information about electroCore is available on their official website at www.electrocore.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ECOR Insider Trading Activity
$ECOR insiders have traded $ECOR stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ECOR stock by insiders over the last 6 months:
- THOMAS J. ERRICO has made 2 purchases buying 25,000 shares for an estimated $114,785 and 0 sales.
- JOHN P GANDOLFO purchased 1,800 shares for an estimated $9,018
- DANIEL S GOLDBERGER (Chief Executive Officer) purchased 1,000 shares for an estimated $4,230
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ECOR Hedge Fund Activity
We have seen 13 institutional investors add shares of $ECOR stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NEWEDGE ADVISORS, LLC removed 99,999 shares (-61.7%) from their portfolio in Q2 2025, for an estimated $527,994
- PERRITT CAPITAL MANAGEMENT INC added 69,200 shares (+692.0%) to their portfolio in Q2 2025, for an estimated $365,376
- AWM INVESTMENT COMPANY, INC. removed 48,180 shares (-15.1%) from their portfolio in Q2 2025, for an estimated $254,390
- JANE STREET GROUP, LLC removed 36,726 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $193,913
- INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC added 30,550 shares (+65.7%) to their portfolio in Q2 2025, for an estimated $161,304
- CUBIST SYSTEMATIC STRATEGIES, LLC removed 22,800 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $120,384
- TWO SIGMA INVESTMENTS, LP added 20,372 shares (+inf%) to their portfolio in Q2 2025, for an estimated $107,564
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025.
Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, November 5, 4:30 PM EST
Dial-In:
(646) 931-3860
Webinar ID:
822 9598 1338
Passcode:
454695
Registration Link:
Click here
to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com .
Contact
ECOR Investor Relations
(973) 302-9253
[email protected]
